최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Cell research, v.10 no.4, 2000년, pp.245 - 266
ROTHSTEIN, Thomas L
Apoptosis produced in B cells through Fas (APO-1, CD95) triggering is regulated by signals derived from other surface receptors: CD40 engagement produces upregulation of Fas expression and marked susceptibility to Fas-induced cell death, whereas antigen receptor engagement, or IL-4R engagement, inhi...
J Exp Med S Yonehara 169 1747 1989 10.1084/jem.169.5.1747 Yonehara S, Ishii A, Yonehara M . A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169:1747-56.
Science BC Trauth 245 301 1989 10.1126/science.2787530 Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody- mediated tumor regression by induction of apoptosis. Science 1989; 245:301-5.
Cell S Nagata 88 355 1997 10.1016/S0092-8674(00)81874-7 Nagata S . Apoptosis by death factor. Cell 1997; 88:355-65.
Science AM Chinnaiyan 274 990 1996 10.1126/science.274.5289.990 Chinnaiyan AM, O'Rourke K, Yu GL, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996;,B. 274:990-2.
Immunity PM Chaudhary 7 821 1997 10.1016/S1074-7613(00)80400-8 Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L . Death receptor 5, a new member of the TNFR family, and DR4 induce FADD- dependent apoptosis and activate the NF- κ B pathway. Immunity 1997; 7:821-30.
Immunity P Schneider 7 831 1997 10.1016/S1074-7613(00)80401-X Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 1997; 7:831-6.
Science WC Yeh 279 1954 1998 10.1126/science.279.5358.1954 Yeh WC, Pompa JL, McCurrach ME, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998; 279:1954-8.
J Immunol T Suda 154 3806 1995 10.4049/jimmunol.154.8.3806 Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154:3806-13.
Transplantation MJ Smyth 62 1529 1996 10.1097/00007890-199611270-00030 Smyth MJ, Sutton VR, Kershaw MH, Trapani JA . Xenospecific cytotoxic T lymphocytes use perforin- and Fas-mediated lytic pathways. Transplantation 1996; 62:1529-32.
Immunol Rev S Hahn 146 57 1995 10.1111/j.1600-065X.1995.tb00684.x Hahn S, Gehri R, Erb P . Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 1995; 146:57-79.
J Exp Med H Arase 181 1235 1995 10.1084/jem.181.3.1235 Arase H, Arase N, Saito T . Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995; 181:1235-8.
Cell Immunol AH Montel 166 236 1995 10.1006/cimm.1995.9974 Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z . Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 1995; 166:236-46.
J Immunol Y Oshimi 157 2909 1996 10.4049/jimmunol.157.7.2909 Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S . Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 1996; 157:2909-15.
Annu Rev Immunol PL Cohen 9 243 1991 10.1146/annurev.iy.09.040191.001331 Cohen PL, Eisenberg RA . Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9:243-69.
Nature R Watanabe-Fukunaga 356 314 1992 10.1038/356314a0 Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S . Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
Cell T Takahashi 76 969 1994 10.1016/0092-8674(94)90375-1 Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76:969-76.
Cell GH Fisher 81 935 1995 10.1016/0092-8674(95)90013-6 Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81:935-46.
Science F Rieux-Laucat 268 1347 1995 10.1126/science.7539157 Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268:1347-9.
N Engl J Med J Drappa 335 1643 1996 10.1056/NEJM199611283352204 Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB . Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity [see comments]. N Engl J Med 1996; 335:1643-9.
J Clin Invest J Wu 98 1107 1996 10.1172/JCI118892 Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD . Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996; 98:1107-13.
Lancet F Le Deist 348 719 1996 10.1016/S0140-6736(96)02293-3 Le Deist F, Emile JF, Rieux- Laucat F, et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 1996; 348:719-23.
Cell J Wang 98 47 1999 10.1016/S0092-8674(00)80605-4 Wang J, Zheng L, Lobito A, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999; 98:47-58.
Immunol Today S Nagata 16 39 1995 10.1016/0167-5699(95)80069-7 Nagata S, Suda T . Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16:39-43.
Proc Natl Acad Sci U S A M Adachi 93 2131 1996 10.1073/pnas.93.5.2131 Adachi M, Suematsu S, Suda T, et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci U S A 1996; 93:2131-6.
J Immunol DL Perkins 139 1406 1987 10.4049/jimmunol.139.5.1406 Perkins DL, Michaelson J, Glaser RM, Marshak-Rothstein A . Selective elimination of non- lpr lymphoid cells in mice undergoing lpr-mediated graft-vs-host disease. J Immunol 1987; 139:1406-13.
J Immunol D Nemazee 147 2536 1991 10.4049/jimmunol.147.8.2536 Nemazee D, Guiet C, Buerki K, Marshak-Rothstein A . B lymphocytes from the autoimmune-prone mouse strain MLR/ lpr manifest an intrinsic defect in tetraparental MRL/ lpr in equilibrium DBA/2 chimeras. J Immunol 1991; 147:2536-9.
J Immunol ES Sobel 160 1497 1998 10.4049/jimmunol.160.3.1497 Sobel ES, Kakkaaiah VN, Schiffenbauer J, Reap EA, Cohen PL, Eisenberg RA . Novel immunoregulatory B cell pathways revealed by lpr-+ mixed chimeras. J Immunol 1998; 160:1497-503.
J Immunol H Fukuyama 160 3805 1998 10.4049/jimmunol.160.8.3805 Fukuyama H, Adachi M, Suematsu S, et al. Transgenic expression of Fas in T cells blocks lymphoproliferation but not autoimmune disease in MRL- lpr mice. J Immunol 1998; 160:3805-11.
J Immunol T Stalder 152 1127 1994 10.4049/jimmunol.152.3.1127 Stalder T, Hahn S, Erb P . Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994; 152:1127-33.
Proc Natl Acad Sci USA ST Ju 91 4185 1994 10.1073/pnas.91.10.4185 Ju ST, Cui H, Panka DJ, Ettinger R, Marshak-Rothstein A . Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 1994; 91:4185-9.
J Immunol PT Daniel 152 5624 1994 10.4049/jimmunol.152.12.5624 Daniel PT, Krammer PH . Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 1994; 152:5624-32.
Int Immunol D Watanabe 7 1949 1995 10.1093/intimm/7.12.1949 Watanabe D, Suda T, Nagata S . Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. Int Immunol 1995; 7:1949-56.
Eur J Immunol KB Onel 25 2940 1995 10.1002/eji.1830251034 Onel KB, Tucek-Szabo CL, Ashany D, Lacy E, Nikolic-Zugic J, Elkon KB . Expression and function of the murine CD95/FasR/APO-1 receptor in relation to B cell ontogeny. Eur J Immunol 1995; 25:2940-7.
Nature TL Rothstein 374 163 1995 10.1038/374163a0 Rothstein TL, Wang JK, Panka DJ, et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995; 374:163-5.
J Immunol LC Foote 157 1878 1996 10.4049/jimmunol.157.5.1878 Foote LC, Schneider TJ, Fischer GM, et al. Intracellular signaling for inducible antigen receptor-mediated Fas resistance in B cells. J Immunol 1996; 157:1878-85.
J Exp Med LC Foote 187 847 1998 10.1084/jem.187.6.847 Foote LC, Marshak-Rothstein A, Rothstein TL . Tolerant B lymphocytes acquire resistance to Fas-mediated apoptosis after treatment with interleukin 4 but not after treatment with specific antigen unless a surface immunoglobulin threshold is exceeded. J Exp Med 1998; 187:847-53.
J Immunol LC Foote 157 2749 1996 10.4049/jimmunol.157.7.2749 Foote LC, Howard RG, Marshak-Rothstein A, Rothstein TL . IL-4 induces Fas resistance in B cells. J Immunol 1996; 157:2749-53.
J Exp Med EJ Schattner 182 1557 1995 10.1084/jem.182.5.1557 Schattner EJ, Elkon KB, Yoo DH, et al. CD40 ligation induces Apo- 1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995; 182:1557-65.
J Exp Med P Garrone 182 1265 1995 10.1084/jem.182.5.1265 Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J . Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 1995; 182:1265-73.
J Exp Med C Lagresle 183 1377 1996 10.1084/jem.183.4.1377 Lagresle C, Mondiere P, Bella C, Krammer PH, Defrance T . Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis. J Exp Med 1996; 183:1377-88.
Cell JC Rathmell 87 319 1996 10.1016/S0092-8674(00)81349-5 Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC . Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996; 87:319-29.
Wurster AL, Rothstein TL, Grusby MJ . IL-4 protects primary B cells from apoptosis through Stat6-dependent upregulation of Bcl-xL. Submitted.
J Immunol JG Karras 157 39 1996 10.4049/jimmunol.157.1.39 Karras JG, Wang Z, Coniglio SJ, Frank DA, Rothstein TL . Antigen-receptor engagement in B cells induces nuclear expression of STAT5 and STAT6 proteins that bind and transactivate an IFN-γ activation site. J Immunol 1996; 157:39-47.
Eur J Immunol GG Klaus 16 92 1986 10.1002/eji.1830160118 Klaus GG, O'Garra A, Bijsterbosch MK, Holman M . Activation and proliferation signals in mouse B cells. VIII. Induction of DNA synthesis in B cells by a combination of calcium ionophores and phorbol myristate acetate. Eur J Immunol 1986; 16:92-7.
Cell Immunol TL Rothstein 102 364 1986 10.1016/0008-8749(86)90430-2 Rothstein TL, Baeker TR, Miller RA, Kolber DL . Stimulation of murine B cells by the combination of calcium ionophore plus phorbol ester. Cell Immunol 1986; 102:364-73.
J Exp Med DG Sieckmann 147 814 1978 10.1084/jem.147.3.814 Sieckmann DG, Asofsky R, Mosier DE, Zitron IM, Paul . Activation of mouse lymphocytes by anti-immunoglobulin. I. Parameters of the proliferative response. J Exp Med 1978; 147:814-29.
Science DJ Rawlings 261 358 1993 10.1126/science.8332901 Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993; 261:358-61.
Immunity WN Khan 3 283 1995 10.1016/1074-7613(95)90114-0 Khan WN, Alt FW, Gerstein RM, et al. Defective B cell development and function in Btk-deficient mice. Immunity 1995; 3:283-99.
Negm RS, Schneider TJ, Colarusso TP, Woodland RT, Rothstein TL . Btk does not regulate susceptibility to Fas-mediated apoptosis nor inducible Fas-resistance in murine B cells. In preparation 2000; .
J Biol Chem A Vassilev 274 1646 1999 10.1074/jbc.274.3.1646 Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM . Bruton' s tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 1999; 274:1646-56.
J Exp Med TJ Schneider 189 949 1999 10.1084/jem.189.6.949 Schneider TJ, Fischer GM, Donohoe TJ, Colarusso TP, Rothstein TL . A novel gene coding for a Fas apoptosis inhibitory molecule (FAIM) isolated from inducibly Fas-resistant B lymphocytes. J Exp Med 1999; 189:949-56.
J Immunol IM Catlett 163 2378 1999 10.4049/jimmunol.163.5.2378 Catlett IM, Bishop GA . Cutting edge: a novel mechanism for rescue of B cells from CD95/Fas-mediated apoptosis. J Immunol 1999; 163:2378-81.
J Immunol JL Liu 146 1685 1991 10.4049/jimmunol.146.5.1685 Liu JL, Chiles TC, Sen RJ, Rothstein TL . Inducible nuclear expression of NF-κB in primary B cells stimulated through the surface Ig receptor. J Immunol 1991; 146:1685-91.
Eur J Immunol JW Rooney 21 2993 1991 10.1002/eji.1830211214 Rooney JW, Dubois PM, Sibley CH . Cross-linking of surface IgM activates NF-κB in B lymphocyte. Eur J Immunol 1991; 21:2993-8.
Immunol Res S Ghosh 19 183 1999 10.1007/BF02786486 Ghosh S . Regulation of inducible gene expression by the transcription factor NF- κ B. Immunol Res 1999; 19:183-9.
Blood I Jeremias 91 4624 1998 10.1182/blood.V91.12.4624 Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM . Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91:4624-31.
Eur J Immunol E Dudley 29 878 1999 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9 Dudley E, Hornung F, Zheng L, Scherer D, Ballard D, Lenardo M . NF-κB regulates Fas/APO-1/CD95- and TCR-mediated apoptosis of T lymphocytes. Eur J Immunol 1999; 29:878-86.
Genes Dev WX Zong 13 382 1999 10.1101/gad.13.4.382 Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C . The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NFκ-B that blocks TNF α-induced apoptosis. Genes Dev 1999; 13:382-7.
Genes Dev RJ Grumont 13 400 1999 10.1101/gad.13.4.400 Grumont RJ, Rourke IJ, Gerondakis S . Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999; 13:400-11.
Proc Natl Acad Sci USA HH Lee 96 9136 1999 10.1073/pnas.96.16.9136 Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G . NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999; 96:9136-41.
Mol Cell Biol CY Wang 19 5923 1999 10.1128/MCB.19.9.5923 Wang CY, Guttridge DC, Mayo MW, Baldwin AS, Jr . NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923-9.
Science G Fenteany 268 726 1995 10.1126/science.7732382 Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL . Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995; 268:726-31.
Eur J Immunol K Matsui 27 2269 1997 10.1002/eji.1830270922 Matsui K, Omura S, Cui H, Schauer SL, Sonenshein GE, Ju ST . Proteasome regulation of Fas ligand cytotoxicity. Eur J Immunol 1997; 27:2269-78.
J Exp Med R Schreck 175 1181 1992 10.1084/jem.175.5.1181 Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA . Dithiocarbamates as potent inhibitors of nuclear factor κ B activation in intact cells. J Exp Med 1992; 175:1181-94.
J Exp Med UD Bajpai 191 1735 2000 10.1084/jem.191.10.1735 Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH . Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation. J Exp Med 2000; 191:1735-44.
J Exp Med JB Petro 191 1745 2000 10.1084/jem.191.10.1745 Petro JB, Rahman SM, Ballard DW, Khan WN . Bruton's tyrosine kinase is required for activation of I κ B kinase and nuclear factor κ B in response to B cell receptor engagement. J Exp Med 2000; 191:1745-54.
Blood E Yang 88 386 1996 10.1182/blood.V88.2.386.bloodjournal882386 Yang E, Korsmeyer SJ . Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996; 88:386-401.
J Immunol TJ Schneider 159 4834 1997 10.4049/jimmunol.159.10.4834 Schneider TJ, Grillot D, Foote LC, Nunez GE, Rothstein TL . Bcl-x protects primary B cells against Fas-mediated apoptosis. J Immunol 1997; 159:4834-9.
Cell Immunol X Zhang 173 149 1996 10.1006/cimm.1996.0260 Zhang X, Li L, Choe J, et al. Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis. Cell Immunol 1996; 173:149-54.
Proc Natl Acad Sci USA DC Huang 96 14871 1999 10.1073/pnas.96.26.14871 Huang DC, Hahne M, Schroeter M, et al. Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proc Natl Acad Sci USA 1999; 96:14871-6.
J Exp Med N Zamzami 182 367 1995 10.1084/jem.182.2.367 Zamzami N, Marchetti P, Castedo M, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995; 182:367-77.
Cancer Res D Decaudin 57 62 1997 Decaudin D, Geley S, Hirsch T, et al. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997; 57:62-7.
Hepatology AS Arora 25 958 1997 10.1002/hep.510250428 Arora AS, Jones BJ, Patel TC, Bronk SF, Gores GJ . Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology 1997; 25:958-63.
J Biol Chem TI Gudz 272 24154 1997 10.1074/jbc.272.39.24154 Gudz TI, Tserng KY, Hoppel CL . Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem 1997; 272:24154-8.
J Biol Chem C Scaffidi 274 22532 1999 10.1074/jbc.274.32.22532 Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME . Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 1999; 274:22532-8.
Nature M Irmler 388 190 1997 10.1038/40657 Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP [see comments]. Nature 1997; 388:190-5.
J Biol Chem S Hu 272 17255 1997 10.1074/jbc.272.28.17255 Hu S, Vincenz C, Ni J, Gentz R, Dixit VM . I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD- 95-induced apoptosis. J Biol Chem 1997; 272:17255-7.
J Biol Chem SM Srinivasula 272 18542 1997 10.1074/jbc.272.30.18542 Srinivasula SM, Ahmad M, Ottilie S, et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 1997; 272:18542-5.
J Biol Chem YV Goltsev 272 19641 1997 10.1074/jbc.272.32.19641 Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, Wallach D . CASH, a novel caspase homologue with death effector domains. J Biol Chem 1997; 272:19641-4.
Immunity L Van Parijs 11 763 1999 10.1016/S1074-7613(00)80150-8 Van Parijs L, Refaeli Y, Abbas AK, Baltimore D . Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes. Immunity 1999; 11:763-70.
Eur J Immunol J Wang 30 155 2000 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.0.CO;2-X Wang J, Lobito AA, Shen F, Hornung F, Winoto A, Lenardo MJ . Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur J Immunol 2000; 30:155-63.
J Immunol EY Lin 151 1979 1993 10.4049/jimmunol.151.4.1979 Lin EY, Orlofsky A, Berger MS, Prystowsky MB . Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 1993; 151:1979-88.
J Biol Chem A Krikos 267 17971 1992 10.1016/S0021-9258(19)37138-8 Krikos A, Laherty CD, Dixit VM . Transcriptional activation of the tumor necrosis factor α-inducible zinc finger protein, A20, is mediated by κB elements. J Biol Chem 1992; 267:17971-6.
Cell S Takayama 80 279 1995 10.1016/0092-8674(95)90410-7 Takayama S, Sato T, Krajewski S, et al. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 1995; 80:279-84.
Proc Natl Acad Sci USA L Pegoraro 81 7166 1984 10.1073/pnas.81.22.7166 Pegoraro L, Palumbo A, Erikson J, et al. A 14; 18 and an 8; 14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci USA 1984; 81:7166-70.
Nature D Hockenbery 348 334 1990 10.1038/348334a0 Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ . Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348:334-6.
Cell M Rothe 83 1243 1995 10.1016/0092-8674(95)90149-3 Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV . The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995; 83:1243-52.
Cell L Wang 78 739 1994 10.1016/S0092-8674(94)90422-7 Wang L, Miura M, Bergeron L, Zhu H, Yuan J . Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 1994; 78:739-50.
Science MX Wu 281 998 1998 10.1126/science.281.5379.998 Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF . IEX-1L, an apoptosis inhibitor involved in NF-$\kappa$B-mediated cell survival. Science 1998; 281:998-1001.
Nat Med G Ambrosini 3 917 1997 10.1038/nm0897-917 Ambrosini G, Adida C, Altieri DC . A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917-21.
Science P Liang 257 967 1992 10.1126/science.1354393 Liang P, Pardee AB . Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction [see comments]. Science 1992; 257:967-71.
J Immunol J Mizuguchi 139 1054 1987 10.4049/jimmunol.139.4.1054 Mizuguchi J, Ji YY, Nakabayaschi H, et al. Protein kinase C activation blocks anti-IgM-mediated signaling BAL17 B lymphoma cells. J Immunol 1987; 139:1054-9.
Cell M Tewari 81 801 1995 10.1016/0092-8674(95)90541-3 Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995; 81:801-9.
Nature DW Nicholson 376 37 1995 10.1038/376037a0 Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis [see comments]. Nature 1995; 376:37-43.
Genomics G Lennon 33 151 1996 10.1006/geno.1996.0177 Lennon G, Auffray C, Polymeropoulos M, Soares MB . The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. Genomics 1996; 33:151-2.
Zhong X, Schneider TJ, Donohoe TJ, Rothstein TL . A novel isoform of Fas Apoptosis Inhibitory Molecule (FAIM)--cloning, genomic organization, alternative splicing and restricted expression. Submitted 2000;
Leukemia SC aimondi 3 42 1989 aimondi SC, Dube ID, Valentine MB, et al. Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia. Leukemia 1989; 3:42-7.
Leukemia J Dierlamm 11 747 1997 10.1038/sj.leu.2400635 Dierlamm J, Rosenberg C, Stul M, et al. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia 1997; 11:747-58.
Cancer Res I Petersen 57 2331 1997 Petersen I, Bujard M, Petersen S, et al. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 1997; 57:2331-5.
J Exp Med M Djerbi 190 1025 1999 10.1084/jem.190.7.1025 Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A . The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors [see comments]. J Exp Med 1999; 190:1025-32.
J Exp Med JP Medema 190 1033 1999 10.1084/jem.190.7.1033 Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R . Immune escape of tumors in vivo by expression of cellular FLICE- inhibitory protein [see comments]. J Exp Med 1999; 190:1033-8.
Bioessays L Balvay 15 165 1993 10.1002/bies.950150304 Balvay L, Libri D, Fiszman MY . Pre-mRNA secondary structure and the regulation of splicing. Bioessays 1993; 15:165-9.
Trends Genet T Cavalier-Smith 7 145 1991 10.1016/0168-9525(91)90102-V Cavalier-Smith T . Intron phylogeny: a new hypothesis. Trends Genet 1991; 7:145-8.
Curr Opin Genet Dev JD Palmer 1 470 1991 10.1016/S0959-437X(05)80194-7 Palmer JD, Logsdon JM, Jr . The recent origins of introns. Curr Opin Genet Dev 1991; 1:470-7.
Cell P Lomedico 18 545 1979 10.1016/0092-8674(79)90071-0 Lomedico P, Rosenthal N, Efstratidadis A, Gilbert W, Kolodner R, Tizard R . The structure and evolution of the two nonallelic rat preproinsulin genes. Cell 1979; 18:545-58.
J Lipid Res WH Li 29 245 1988 10.1016/S0022-2275(20)38532-1 Li WH, Tanimura M, Luo CC, Datta S, Chan L . The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res 1988; 29:245-71.
Genetics JA Frugoli 149 355 1998 10.1093/genetics/149.1.355 Frugoli JA, McPeek MA, Thomas TL, McClung CR . Intron loss and gain during evolution of the catalase gene family in angiosperms. Genetics 1998; 149:355-65.
Eur J Immunol P Lane 22 2573 1992 10.1002/eji.1830221016 Lane P, Traunecker A, Hubele S, Inui S, Lanzavecchia A, Gray D . Activated human T cells expre ss a ligand for the human B cell- associated antigen CD40 which participates in T cell- dependent activation of B lymphocytes. Eur J Immunol 1992; 22:2573-8.
Proc Natl Acad Sci USA RJ Noelle 89 6550 1992 10.1073/pnas.89.14.6550 Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A . A 39- kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992; 89:6550-4.
Nature RJ Armitage 357 80 1992 10.1038/357080a0 Armitage RJ, Fanslow WC, Strockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357:80-2.
Nature ST Ju 373 444 1995 10.1038/373444a0 Ju ST, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation [see comments]. Nature 1995; 373:444-8.
Nature T Brunner 373 441 1995 10.1038/373441a0 Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas [see comments]. Nature 1995; 373:441-4.
Nature J Dhein 373 438 1995 10.1038/373438a0 Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH . Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) [see comments]. Nature 1995; 373:438-41.
J Exp Med MR Alderson 181 71 1995 10.1084/jem.181.1.71 Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181:71-7.
Eur J Immunol M Ozdemirli 26 415 1996 10.1002/eji.1830260222 Ozdemirli M, El-Khatib M, Foote LC, et al. Fas (CD95)/Fas ligand interactions regulate antigen-specific, major histocompatibility complex-restricted T/B cell proliferative responses. Eur J Immunol 1996; 26:415-9.
10.1002/1521-4141(200003)30:3<931::AID-IMMU931>3.0.CO;2-H Wang JKM, Ju ST, Marshak-Rothstein A . Protection of T cells from activation-induced cell death by Fas+ B cells. Eur J Immunol 2000; in press.
Nature MJ Shlomchik 328 805 1987 10.1038/328805a0 Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL, Weigert MG . The role of clonal selection and somatic mutation in autoimmunity. Nature 1987; 328:805-11.
Clin Immunol Immunopathol CB Wolfowicz 46 382 1988 10.1016/0090-1229(88)90057-8 Wolfowicz CB, Sakorafas P, Rothstein TL, Marshak-Rothstein A . Oligoclonality of rheumatoid factors arising spontaneously in lor/ lpr mice. Clin Immunol Immunopathol 1988; 46:382-95.
J Exp Med M Shlomchik 171 265 1990 10.1084/jem.171.1.265 Shlomchik M, Mascelli M, Shan H, et al. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J Exp Med 1990; 171:265-92.
Nature JC Rathmell 376 181 1995 10.1038/376181a0 Rathmell JC, Cooke MP, Ho WY, et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 1995; 376:181-4.
J Exp Med H Wang 190 639 1999 10.1084/jem.190.5.639 Wang H, Shlomchik MJ . Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice. J Exp Med 1999; 190:639-49.
J Exp Med MP Cooke 179 425 1994 10.1084/jem.179.2.425 Cooke MP, Heath AW, Shokat KM, et al. Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med 1994; 179:425-38.
Proc Natl Acad Sci USA JM Eris 91 4392 1994 10.1073/pnas.91.10.4392 Eris JM, Basten A, Brink R, Doherty K, Kehry MR, Hodgkin PD . Anergic self-reactive B cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions. Proc Natl Acad Sci USA 1994; 91:4392-6.
J Exp Med WY Ho 179 1539 1994 10.1084/jem.179.5.1539 Ho WY, Cooke MP, Goodnow CC, Davis MM . Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J Exp Med 1994; 179:1539-49.
J Immunol HJ Burstein 147 2950 1991 10.4049/jimmunol.147.9.2950 Burstein HJ, Tepper RI, Leder P, Abbas AK . Humoral immune functions in IL-4 transgenic mice. J Immunol 1991; 147:2950-6.
J Exp Med KJ Erb 185 329 1997 10.1084/jem.185.2.329 Erb KJ, Ruger B, von Brevern M, Ryffel B, Schimpl A, Rivett K . Constitutive expression of interleukin (IL)-4 {\sl in vivo} causes autoimmune- type disorders in mice. J Exp Med 1997; 185:329-39.
J Exp Med JC Rathmell 188 651 1998 10.1084/jem.188.4.651 Rathmell JC, Fournier S, Weintraub BC, Allison JP, Goodnow CC . Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. J Exp Med 1998; 188:651-9.
Arch Surg JT DiPiro 130 1159 1995 10.1001/archsurg.1995.01430110017004 DiPiro JT, Howdieshell TR, Goddard JK, Callaway DB, Hamilton RG, Mansberger AR, Jr . Association of interleukin-4 plasma levels with traumatic injury and clinical course. Arch Surg 1995; 130:1159-62; discussion 1162-3.
Int Immunol C Klas 5 625 1993 10.1093/intimm/5.6.625 Klas C, Debatin KM, Jonker RR, Krammer PH . Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5:625-30.
Immunity Y Refaeli 8 615 1998 10.1016/S1074-7613(00)80566-X Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK . Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998; 8:615-23.
J Immunol HE Broome 155 2311 1995 10.4049/jimmunol.155.5.2311 Broome HE, Dargan CM, Krajewski S, Reed JC . Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal. J Immunol 1995; 155:2311-7.
Eur J Immunol ME Peter 27 1207 1997 10.1002/eji.1830270523 Peter ME, Kischkel FC, Scheuerpflug CG, Medema JP, Debatin KM, Krammer PH . Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur J Immunol 1997; 27:1207-12.
J Biol Chem C Scaffidi 274 1541 1999 10.1074/jbc.274.3.1541 Scaffidi C, Schmitz I, Krammer PH, Peter ME . The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274:1541-8.
Eur J Immunol T Miethke 26 1459 1996 10.1002/eji.1830260709 Miethke T, Vabulas R, Bittlingmaier R, Heeg K, Wagner H . Mechanisms of peripheral T cell deletion: anergized T cells are Fas resistant but undergo proliferation-associated apoptosis. Eur J Immunol 1996; 26:1459-67.
J Immunol VA Boussiotis 159 3156 1997 10.4049/jimmunol.159.7.3156 Boussiotis VA, Lee BJ, Freeman GJ, Gribben JG, Nadler LM . Induction of T cell clonal anergy results in resistance, whereas CD28- mediated costimulation primes for susceptibility to Fas- and Bax- mediated programmed cell death. J Immunol 1997; 159:3156-67.
J Exp Med X Zhang 185 1837 1997 10.1084/jem.185.10.1837 Zhang X, Brunner T, Carter L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997; 185:1837-49.
Proc Natl Acad Sci USA AS Varadhachary 94 5778 1997 10.1073/pnas.94.11.5778 Varadhachary AS, Perdow SN, Hu C, Ramanarayanan M, Salgame P . Differential ability of T cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci USA 1997; 94:5778-83.
J Immunol MM Di Somma 162 3851 1999 10.4049/jimmunol.162.7.3851 Di Somma MM, Somma F, Montani MS, Mangiacasale R, Cundari E, Piccolella E . TCR engagement regulates differential responsiveness of human memory T cells to Fas (CD95)-mediated apoptosis. J Immunol 1999; 162:3851-8.
J Immunol M Inaba 163 1315 1999 10.4049/jimmunol.163.3.1315 Inaba M, Kurasawa K, Mamura M, Kumano K, Saito Y, Iwamoto I . Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells. J Immunol 1999; 163:1315-20.
Leukemia P Panayiotidis 9 1227 1995 Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV . Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 1995; 9:1227-32.
Leukemia L Xerri 11 1868 1997 10.1038/sj.leu.2400815 Xerri L, Devilard E, Hassoun J, Haddad P, Birg F . Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 1997; 11:1868-77.
Blood J Plumas 91 2875 1998 10.1182/blood.V91.8.2875.2875_2875_2885 Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC . Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998; 91:2875-85.
Br J Haematol L Xerri 106 652 1999 10.1046/j.1365-2141.1999.01586.x Xerri L, Devilard E, Bouabdallah R, Stoppa AM, Hassoun J, Birg F . FADD expression and caspase activation in B-cell lymphomas resistant to Fas-mediated apoptosis. Br J Haematol 1999; 106:652-61.
Cancer Res LB Owen-Schaub 54 1580 1994 Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S . Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994; 54:1580-6.
Oncogene G Natoli 11 1157 1995 Natoli G, Ianni A, Costanzo A, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11:1157-64.
Cancer Res MM Keane 56 4791 1996 Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S . Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56:4791-8.
Cancer Res H Ungefroren 58 1741 1998 Ungefroren H, Voss M, Jansen M, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998; 58:1741-9.
Prostate TE Hedlund 36 92 1998 10.1002/(SICI)1097-0045(19980701)36:2<92::AID-PROS4>3.0.CO;2-G Hedlund TE, Duke RC, Schleicher MS, Miller GJ . Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate 1998; 36:92-101.
Gynecol Oncol RL Baldwin 74 265 1999 10.1006/gyno.1999.5448 Baldwin RL, Tran H, Karlan BY . Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. Gynecol Oncol 1999; 74:265-71.
J Exp Med SL Peng 184 1149 1996 10.1084/jem.184.3.1149 Peng SL, Robert ME, Hayday AC, Craft J . A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 1996; 184:1149-54.
Immunity D Traver 9 47 1998 10.1016/S1074-7613(00)80587-7 Traver D, Akashi K, Weissman IL, Lagasse E . Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 1998; 9:47-57.
J Exp Med WF Davidson 187 1825 1998 10.1084/jem.187.11.1825 Davidson WF, Giese T, Fredrickson TN . Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998; 187:1825-38.
J Exp Med LB Owen-Schaub 188 1717 1998 10.1084/jem.188.9.1717 Owen-Schaub LB, van Golen KL, Hill LL, Price JE . Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 1998; 188:1717-23.
J Immunol RR Furman 164 2200 2000 10.4049/jimmunol.164.4.2200 Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ . Modulation of NF-κB activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164:2200-6.
Int J Cancer S Ugurel 82 727 1999 10.1002/(SICI)1097-0215(19990827)82:5<727::AID-IJC17>3.0.CO;2-E Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U . Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon- γ. Int J Cancer 1999; 82:727-36.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.